{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR003966",
      "entity_text" : "thrombin",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01502",
      "entity_text" : "emicizumab's FVIIIa cofactor",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Because thrombin generation assays cannot distinguish between the potential blocking effects of emicizumab on AT or TFPI 's action versus the effect of emicizumab 's FVIIIa cofactor function, both of which would increase thrombin generation, we first had to prevent the effect of emicizumab 's FVIIIa cofactor function on coagulation.",
  "reading_complete" : "2020-08-03T12:56:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T12:54:35Z",
  "trigger" : "increase",
  "evidence" : [ "emicizumab's FVIIIa cofactor function, both of which would increase thrombin" ],
  "pmc_id" : "6524866",
  "score" : 0
}